SYNOPSIS The administration of oral contraceptives which contain oestrogen increases non-protein-bound plasma cortisol levels at 9 am as well as protein-bound and total cortisol levels. These increases are dependent on the dose of oestrogen; they are not usually seen with progestogen-only or 'low-dose' oestrogen (0.05 mg mestranol or less) preparations. 'Standard' oral contraceptives (0.1 mg mestranol or equivalent) produce some elevation of unbound cortisol levels at 9 am (from a normal mean of 0.66 ,ug/100 ml to 1.02 on the 'pill') but this elevation is less than that associated with high-dose oestrogen treatment of, for example, prostate cancer (mean 1.8 ,ug/100 ml). Since unbound cortisol levels in plasma are controlled by a hypothalamic feedback mechanism, it appears that oral contraceptives have some effect on this mechanism. Possible long-term effects of oral contraceptives on hypothalamopituitary function require examination.
Much has been published concerning the effect of administering various steroids upon cortisol metabolism; in the case of oral contraceptives these effects relate largely to the otstrogen component, for administration of progestogens alone has not been shown to have any consistent effect on cortisol metabolism. The literature relating to the effects of oestrogen on cortisol metabolism is complex. The purpose of this paper is to show how a simple approach suggests that the effect of oral contraceptives in increasing general tissue exposure to cortisol is slight, and is related to the daily oestrogen dose. However, it must be conceded that standard oral contraceptives cause gross disturbances of cortisol metabolism which raise doubt about the wisdom of taking them for long periods.
It has long been known that oestrogens increase total plasma cortisol levels but do not increase urinary excretion of cortisol metabolites (Robertson, Stiefel, and Laidlaw, 1959; Peterson, Nokes, Chen, and Black, 1960) . The conflict between this observation and the fact that oestrogen-treated subjects do not clinically resemble patients with Cushing's syndrome having similar plasma cortisol levels was clarified by the demonstration of oestrogen-induced increases in cortisol binding to plasma proteins (Sandberg and Slaunwhite, 1959; Sandberg, Slaunwhite, and Carter, 1960) . It is quite certain that administering oestrogen causes an increase in plasma levels of corticosteroid-binding globulin (called CBG) (Daughaday, Adler, Mariz, and Rasinski, 1962; De Moore, Steeno, Brosens, and Hendrikx, 1966; Doe, Fernandez, and Seal, 1964) . The magnitude of this increase is dependent on the dose of oestrogen given (Doe, Mellinger, Swaim, and Seal, 1967a) . The increase in corticosteroidbinding globulin concentration is not apparently due to its increased catabolism (Sandberg, Woodruff, Rosenthal, Nienhouse, and Slaunwhite, 1964) ; it is probably due to increased hepatic synthesis of corticosteroid-binding globulin, in parallel with the rises in other specific serum proteins induced by oestrogen (Musa, Doe, and Seal, 1967) . The raised level of corticosteroid-binding globulin falls to normal within two to three weeks after stopping the oestrogen. Increased levels are not produced by progesterone or prevented by androgens (Sandberg et al, 1960) .
Increased CBG-bound cortisol in the plasma of oestrogen-treated subjects has been demonstrated directly (Doe, Zinneman, Flink, and Ulstrom, 1960; Mills, Schedl, Chen, and Bartter, 1960) . The importance of this is that cortisol is biologically not available to most tissues as long as it remains bound to corticosteroid-binding globulin (Slaunwhite, Lockie, Back, and Sandberg, 1962; Blecher, 1966; Matsui and Plager, 1966) . For this reason much interest has centred round non-protein-bound cortisol levels in oestrogen-treated subjects. Early reports (Doe et al, 1960; Mills et al, 1960; Plager, Schmidt, and Staubitz, 1964) gave contradictory results for unbound cortisol levels in oestrogen-treated subjects, due largely to difficulties with methodology. Later work with better methods bas resolved the discrepancies, the consensus of opinion now being that oestrogen administration increases unbound, biologically active cortisol levels in plasma (Murray, 1967; Doe, Dickinson, Swaim, Zinneman, and Seal, 1967b; Doe, Dickinson, Zinneman, and Seal, 1969; O'Connell and Welsh, 1969) and this is true of oral contraceptives (Burke, 1969a) . When the oestrogen is given cyclically, there is no significant change in unbound cortisol levels during the cycle (O'Connell and Welsh, 1969) .
These findings concern measurement at one or more points in time only. The average effect of oestrogens on cortisol metabolism over 24 hours might be estimated by the rate of production of cortisol; but in fact this is a poor reflection of the tissue exposure to cortisol during oestrogen treatment. The reason for this is that the metabolic clearance rate of cortisol is decreased and the plasma half-life prolonged by oestrogen treatment (Peterson, 1959; Robertson et al, 1959) so that although the miscible pool of cortisol is larger the flux through it is less (Layne et al, 1962) Two factors contribute: the increased protein-bound pool in plasma and extracellular fluid (Sandberg, Rosenthal, Schneider, and Slaunwhite, 1966) (Beisel, Cos, Horton, Chao, and Forsham, 1964 (-----) in a normal subject.
Methods
Free cortisol excretion was measured by competitive protein-binding analysis of dichloromethane extracts of urine (Beardwell, Burke, and Cope, 1968) , the method being based on that of Murphy (1968) . Total plasma cortisol was measured in the about 70% of the plasma 11-hydroxysteroid concentrations in the same samples determined by Mattingly's method (1962) , and were within 10 % of true cortisol concentrations as determined by paper chromatography in 10 samples.
Plasma unbound cortisol was measured by steady-state gel filtration (Burke, 1969b) . This method preserves the labile equilibrium between cortisol and its binding proteins, and is carried out on undiluted plasma at body temperature and pH. The principle is that the plasma sample is passed continuously into a Sephadex G-50 column at 37°C until a steady state is reached. The leading edge of the sample gives up cortisol to the column, so that the first protein fractions in the effluent are devoid of cortisol (Fig. 2) ; this dissociated cortisol is retarded by molecular sieving and overtaken by the fresh incoming sample. When the cortisol concentration in the gel builds up to the unbound cortisol concentration in the incoming sample, no further net dissociation of steroid-protein complexes takes place and the rest of the sample, irrespective of its size, passes through the column at equilibrium. A plateau of cortisol and protein concentrations identical to those in the sample is then seen in the effluent, as shown in Figure 2 . When the supply of sample is stopped, the protein and protein-bound cortisol concentrations in the effluent fall to zero and the equilibrium unbound cortisol present in the column is eluted as a second cortisol plateau by displacement with a suitable buffer. Thus the cortisol concentration in the final effluent plateau is equal to the true non-protein-bound cortisol concentration in the original sample of plasma at 37°C. A sample of this plateau is removed and assayed for cortisol as described above; alternatively its cortisol concentration may be derived from the total plasma cortisol concentration if tritiated cortisol is added to the plasma before gel filtration, by determination of the tritium concentrations in the two cortisol plateaux. The physicochemical principles to be satisfied are discussed elsewhere (Burke, 1969b) . In practice, 10 ml plasma samples can be used on a 20 by 0.9 cm column, the plasma being gassed with 5 % CO2 before analysis to restore pH. The coefficient of variation of 14 replicate estimates of unbound cortisol on pooled serum was 3 5 %.
Subjects
Normal subjects were healthy volunteers from hospital staff. The women taking oral contraceptives were otherwise healthy, and had been taking these drugs for at least six months. Twentyone of these were taking standard oral contraceptives, containing 0.1 mg of mestranol or ethinyloestradiol combined with a variety of progestogens as shown in Table I . Two women were taking chlormadinone acetate, 0.5 mg daily, alone, and four others were taking oral contraceptives which contained 0.05 mg mestranol; the results in these two subgroups were indistinguishable and they were combined as a 'low-dose oestrogen' group. Seven men with prostatic carcinoma who were being treated with a variety of oestrogens equivalent to a daily dose of between 0-2 and 3.0 mestranol per day were studied; none was clinically ill. Ten cases of Cushing's syndrome were included for comparison. Figure 3 shows the increases in plasma ccortisol in the groups studied. Since it seemed likely that the effects of oral contraceptives upon cortisol metabolism might be related to their oestrogen content, the cortisol levels measured were oestrogen treated Cushincg Figure 4 shows the levels of unbound cortisol found at 9 am in the normal and oestrogentreated subjects, and in the patients with Cushing's syndrome. The low-dose oestrogen and progestogen-only preparations had no significant effect on unbound cortisol levels. The 'standard' preparations are associated with a significant rise in the mean level of unbound cortisol at this time of day, but most of the values are within the normal range as previously described (Burke, 1969a (Espiner, 1966; Vagnucci, Hesser, Kozak, Pauk, Lauler, and Thorn, 1965) because plasma unbound cortisol falls to low levels at night. In women taking oral contraceptives also it seems probable that plasma unbound cortisol falls to nearnormal low levels at night, because of the normal urinary free cortisol excretion.
Results

EFFECT OF OESTROGEN DOSAGE ON TOTAL PLASMA CORTISOL LEVELS AT 9 AM
By these criteria the small doses of oestrogen in standard oral contraceptives (0-1 mg mestranol) used in the present study increased exposure in tissues to unbound cortisol very little, except at 9 am; and low-dose oestrogen (005 mg mestranol or less) and progestogen-only oral contraceptives caused no significant change in exposure of tissues to unbound cortisol at all. Thus increased exposure of tissues to unbound cortisol appears to be no more than a minor factor in the metabolic changes produced by oral contraiceptives containing 0-1 mg mestranol, and it is probably an insignificant factor with preparations containing less or no oestrogen.
However, the lack of effect of oral contraceptives on tissue exposure to cortisol must be treated with caution in the case of the liver. The hepatic extraction of cortisol from plasma accounts for more than the non-protein-bound fraction (Tait and Burstein, 1964 group.bmj.com on October 22, 2017 -Published by http://jcp.bmj.com/ Downloaded from hepatic cells in the absence of a capillary wall, thereby apparently inducing enzyme changes. If CBG-bound cortisol is at least partly available to the liver, then the increase in such cortisol caused by oral contraceptives may have relevance to the hepatic changes they apparently cause; no precise evidence on this point is available. Low-dose oestrogen or progestogen-only preparations appear to cause minimal increases in concentration of corticosteroid-binding globulin judging by total plasma cortisol levels.
EFFECTS OF HIGH-DOSE OESTROGENS AND PREGNANCY
This minor elevation of unbound cortisol and insignificant change in urinary free cortisol excretion in women on 'standard' oral contraceptives contrasts sharply with the changes seen in pregnancy. In pregnancy the diurnal rhythm of unbound cortisol is grossly disturbed (Burke, 1970; Doe et al, 1969) and in consequence urinary free cortisol excretion increased. In pregnancy tissue exposure to unbound cortisol, judged by plasma unbound and urinary free cortisol measurements, is increased about threefold. A similar but smaller increase is found in patients treated with high-dose oestrogens for prostatic cancer (Doe et al, 1969) ; and my own preliminary findings in healthy subjects treated with high-dose oestrogens indicate that the exposure of their tissues to unbound cortisol is raised too, though less so than in pregnancy. These elevations of tissue exposure to cortisol with high-dose oestrogen treatment, and especially pregnancy, are also suggested by similar changes in 'cortisol aminoaciduria' (Zinneman, Seal, and Doe, 1967; Doe, Zinneman, Place, and Seal, 1968) . The conclusion may be drawn that high-dose oestrogen treatment does cause increased exposure of tissues to unbound cortisol, but this is less than that found in pregnancy.
HYPOTHALAMIC EFFECTS
The increase in unbound cortisol induced by 'standard' oral contraceptives raises doubts about their long-term use. Unbound cortisol appears to be the fraction of plasma cortisol to which the hypothalamic control mechanism for corticotrophin release responds (Kawai and Yates, 1966) . Raised unbound cortisol levels associated with oestrogen treatment thus imply interference with cortisol homeostasis at hypothalamic level. In the case of oral contraceptives, the extent of this interference is a matter of degree, apparently depending on the dose of oestrogen; but the mechanism of its production and its long-term consequences are quite unknown. It would perhaps be surprising if the disturbances of cortisol metabolism associated with taking oral contraceptives other than 'lowdose' preparations were proved eventually to be completely harmless.
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